Wyatt Neville (eggarea84)

05 for all). Women were more likely to undergo repeat OHT than men (hazard ratio, 2.93; 95% confidence interval, 1.48-5.81; P<.01). After covariate adjustment, female sex and younger age were independently associated with repeat OHT for CAV (P<.05). No differences in the primary outcome as well as the individual outcomes of death, MI, or TVR were noted between sex groups in patients who underwent PCI for CAV. Female patients were more likely to undergo redo OHT for CAV. Younger age at time of initial OHT was associated with a need for repeat OHT. Female patients were more likely to undergo redo OHT for CAV. Younger age at time of initial OHT was associated with a need for repeat OHT. Patients with low-flow, low-gradient (LFLG) aortic stenosis (AS) have the highest risk among all AS patients. Rapid ventricular pacing (RVP) is frequently used during transcatheter aortic valve implantation (TAVI), but may negatively impact critical left ventricular function in these patients. We investigated the effects of RVP in patients with LFLG-AS undergoing implantation of a self-expandable valve prosthesis. In this retrospective study, patients with LFLG-AS were classified according to the number of cumulative RVP episodes. Thirty-one patients with no episodes of RVP, 46 patients with 1 episode, and 40 patients with 2 or more episodes (2+) were identified. Society of Thoracic Surgeons (STS) scores in patients with 0, 1, or 2+ RVP episodes were 5.1% (interquartile range [IQR], 3.5%-8.9%), 6.0% (IQR, 3.8%-8.8%), and 4.8% (3.8%-8.1%), respectively. Peri-interventional adverse events tended to be highest in the group with 1 RVP. Residual aortic regurgitation was in 3.2%, 4.8%, and 2.6% (P=.87) in patshould not be withheld in an attempt to achieve optimal results, even in LFLG-AS patients. To evaluate the safety and efficacy of the Orsiro sirolimus-eluting stent (Biotronik) in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention (pPCI). Specific drug-eluting stent (DES) platforms might influence pPCI success rate in the mid-to-long term. Orsiro, a hybrid sirolimus DES with thin struts and a biodegradable polymer, may potentially cause less stent malapposition, stent-induced inflammation, and mechanical damage, improving clinical outcomes. We retrospectively enrolled all patients who received 1 or more Orsiro DES in the target vessel of pPCI at 9 Italian centers from January 2012 to March 2016. #link# The primary endpoint was a device-oriented composite endpoint (DOCE) of cardiac death, any myocardial infarction clearly attributable to the intervention culprit vessel (TVMI), and ischemic-driven target-lesion revascularization (ID-TLR) at 1-year follow-up. Secondary endpoints were (1) DOCE at 6-month and 3-year follow-up; (2) any definite/probable stent thrombosis; and (3) any major bleeding. The study cohort comprised 353 patients. At 1-year follow-up, we observed a 3.7% cumulative incidence of DOCE, consisting of 11 cardiac deaths (3.1%), 2 TVMIs (0.6%), and 2 ID-TLRs (0.6%). There was only 1 definite stent thrombosis (0.3%) and 8 bleedings (2.4%). Kaplan-Meier analysis showed DOCE-free survival rates of 96.6% at 6 months, 96.3% at 1 year, and 93.8% at 3 years. Our findings support the real-world safety and efficacy of the Orsiro stent for pPCI. Our findings support the real-world safety and efficacy of the Orsiro stent for pPCI. To evaluate the contributions of human leucocyte antigen ( ) class I and II genes in the development of Graves' ophthalmopathy (GO) in a Southern Chinese population. Eight HLA loci were genotyped and analysed in 272 unrelated patients with Graves' disease (GD) or the proptosis and myogenic phenotypes of GO, and 411 ethnically matched control subjects. The allele frequencies of and in the GD, proptosis and myogenic